UCB ups stake in oncology partner

UCB has upped its investment in Wilex, acquiring an additional 6.65 percent of the oncology company's shares to bring its total holdings to about 18 percent. Wilex acquired five oncology projects from UCB in early 2009, and one of those programs--MEK inhibitor WX554--is now in Phase I development. UCB announcement

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.